All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Padeliporfin Vascular Targeted Photodynamic Therapy Safely Produces High Response Rates in Low-Grade Upper Tract Urothelial Cancer

July 8th 2025

Padeliporfin vascular targeted photodynamic therapy was highly active with a tolerable safety profile in low-grade upper tract urothelial cancer.

MB-101 Receives FDA Orphan Drug Designation for Astrocytoma and Glioblastoma

July 8th 2025

The FDA granted orphan drug designation to MB-101 for recurrent diffuse and anaplastic astrocytoma and glioblastoma.

FDA Grants Orphan Drug Designation to FF-10832 for Biliary Tract Cancer

July 8th 2025

FF-10832—an investigational liposomal formulation of gemcitabine—has received orphan drug designation from the FDA for biliary tract cancer.

Updated EHA-EMN Guidelines Include Melphalan Flufenamide for R/R Myeloma

July 8th 2025

The EHA-EMN guidelines now include melphalan flufenamide for certain patients with relapsed/refractory multiple myeloma.

Nogapendekin Alfa Inbakicept Plus BCG Approved in UK for BCG-Unresponsive NMIBC With CIS

July 8th 2025

The combination of nogapendekin alfa inbakicept and BCG is now approved in the United Kingdom for the treatment of patients with NMIBC with CIS.

EXPLORER Shrinks the Time it Takes for Imaging to Spot Cancer

July 8th 2025

Cancer parametric PET imaging with radioactive tracers is reduced from an hour to 20 minutes

Menin Inhibitors Are Poised to Expand Targeted Therapeutics to Broader AML Populations

July 8th 2025

Naval G. Daver, MD, and Eytan M. Stein, MD, discuss how menin inhibitors may transform the treatment paradigm in NPM1-mutant and NUP98 fusion AML.

Bezuclastinib Improves TSS in Non-Advanced Systemic Mastocytosis

July 8th 2025

Bezuclastinib improved total symptom score vs placebo in non-advanced systemic mastocytosis, meeting the primary end point of the SUMMIT trial.

Efficacy of Upfront Panitumumab Plus Intensified Chemo Falls Short in Liver-Limited, Unresectable mCRC

July 7th 2025

Panitumumab plus FOLFIRINOX or mFOLFOX6 did not elicit meaningful responses in previously untreated, liver-limited, RAS/BRAF wild-type unresectable mCRC.

Ivosidenib Has Preliminary Real-World Activity in IDH1-Mutated Cholangiocarcinoma

July 7th 2025

Ivosidenib was effective for the real-world treatment of patients with IDH1-mutated cholangiocarcinoma.

Partial Match Parity: Increasing the Donor Pool for Hematopoietic Stem Cell Transplantation

July 7th 2025

Real-World Analysis Reveals Shorter Survival in KRAS G12C–Mutant Metastatic CRC After First-Line Treatment

July 7th 2025

A real-world analysis showed that patients with KRAS G12C–mutant mCRC had shorter OS and PFS after first-line treatment vs those with non-G12C mutations.

MAIC Analysis Suggests PFS, OS Advantage With Nivolumab/Ipilimumab Over Other First-Line IO Regimens in HCC

July 7th 2025

Efficacy results from a MAIC suggest potential benefit with nivolumab/ipilimumab over other first-line IO-based regimens in first-line unresectable HCC.

EU Approval Is Sought for Niraparib/Abiraterone Acetate Dual-Action Tablet in mHSPC With HRR Gene Alterations

July 7th 2025

European approval is being sought for the combination of niraparib, abiraterone acetate, and prednisone or prednisolone for HRR-mutated mHSPC.

FDA Approves Oncomine Dx Express Test for Tumor Profiling and as Companion Diagnostic for Sunvozertinib in NSCLC

July 7th 2025

The FDA approved the Oncomine Dx Express Test for tumor profiling and as a companion diagnostic for sunvozertinib in non–small cell lung cancer.

FDA Approves Y-90 Resin Microspheres for Unresectable HCC

July 7th 2025

The FDA has approved SIR-Spheres Y-90 resin microspheres for the treatment of patients with unresectable hepatocellular carcinoma.

Attention to Detail and Patience Are Key in the Job Search Process as Oncology Fellows

July 7th 2025

An assistant professor at The Warren Alpert Medical School of Brown University discusses offers insights on the job search process following fellowship.

PAOLA-1 Analysis Shows PD-L1 Expression Correlates With HRD Positivity in High-Grade Serous Ovarian Cancer

July 7th 2025

PD-L1 expression was more common in HRD-positive high-grade serous ovarian cancer, indicating potential prognostic value in newly diagnosed cases.

mFOLFIRINOX Does Not Significantly Improve Survival Vs mFOLFOX6 in HER2– Metastatic Gastric/GEJ Adenocarcinoma

July 6th 2025

IRIGA trial comparing mFOLFIRINOX vs mFOLFOX6 shows mixed results in HER2-negative metastatic gastric and GEJ adenocarcinoma.

Five Under 5: Top Oncology Videos for the Week of 6/29

July 6th 2025

The top 5 OncLive videos of the week cover insights in myelofibrosis, AL amyloidosis, pancreatic cancer, and PIK3CA-mutated breast cancer.

x